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A B S T R A C T
Expression of CCL2 (CC chemokine ligand 2) (or monocyte chemoattractant protein-1) regulates
inflammatory cell infiltration in the liver and adipose tissue, favouring steatosis. However, its
role in the pathogenesis of steatohepatitis is still uncertain. In the present study, we investigated
the development of non-alcoholic steatohepatitis induced by an MCD diet (methionine/choline-
deficient diet) in mice lacking the CCL2 gene on two different genetic backgrounds, namely Balb/C
and C57/Bl6J. WT (wild-type) and CCL2-KO (knockout) mice were fed on a lipid-enriched MCD
diet or a control diet for 8 weeks. In Balb/C mice fed on the MCD diet, a lack of CCL2 was
associated with lower ALT (alanine transaminase) levels and reduced infiltration of inflammatory
cells, together with a lower generation of oxidative-stress-related products. Sirius Red staining
demonstrated pericellular fibrosis in zone 3, and image analysis showed a significantly lower matrix
accumulation in CCL2-KO mice. This was associated with reduced hepatic expression of TGF-β
(transforming growth factor-β), type I procollagen, TIMP-1 (tissue inhibitor of metalloproteinases-
1) and α-smooth muscle actin. In contrast, in mice on a C57Bl/6 background, neither ALT levels nor
inflammation or fibrosis were significantly different comparingWT and CCL2-KO animals fed on an
MCD diet. In agreement, genes related to fibrogenesis were expressed to comparable levels in the
two groups of animals. Comparison of the expression of several genes involved in inflammation and
repair demonstrated that IL (interleukin)-4 and the M2 marker MGL-1 (macrophage galactose-
type C-type lectin 1) were differentially expressed in Balb/C and C57Bl/6 mice. No significant
differences in the degree of steatosis were observed in all groups of mice fed on the MCD diet.
We conclude that, in experimental murine steatohepatitis, the effects of CCL2 deficiency are
markedly dependent on the genetic background.
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interferon-γ ; IL, interleukin; iNOS, inducible NO synthase; KO, knockout; MCD diet, methionine/choline-deficient diet; MGL1,
macrophage galactose-type C-type lectin 1; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; ROS,
reactive oxygen species; RT, real-time; TGF-β, transforming growth factor-β; TIMP-1, tissue inhibitor of metalloproteinases-1;
TNFα, tumour necrosis factor α; WT, wild-type.
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INTRODUCTION
NAFLD (non-alcoholic fatty liver disease) is the most
common cause of chronic liver disease in the Western
world [1]. A fraction of patients with NAFLD shows
findings of NASH (non-alcoholic steatohepatitis), which
is characterized by hepatocellular injury, inflammation
and fibrosis [2]. In this case, parenchymal injury and
inflammation are associatedwith generation of oxidative-
stress-related products, which have a deleterious
impact on disease progression [2]. More importantly,
NASH potentially leads to fibrosis, cirrhosis and its
complications.
Understanding the cellular and molecular mechanisms
that are responsible for hepatic damage and fibrogenesis
is of key relevance in the field of fatty liver. Several
lines of evidence suggest that cytokines represent relevant
mediators in this context. In particular, different pro-
inflammatory cytokines are up-regulated in the liver of
patients with NAFLD, and their expression correlates
with parameters of inflammation and/or fibrogenesis [3].
Among cytokines, attention has been recently directed
to the chemokine family of pro-inflammatory factors.
Chemokines are a class of small cytokines that are
involved in the regulation of leukocyte recruitment
to different tissues, including the liver and orchestrate
inflammatory responses [4].
CCL2 (CC chemokine ligand 2), also known as
MCP-1 (monocyte chemoattractant protein-1), is an
inflammatory chemokine that targets predominantly
monocytes and T-lymphocytes [5]. In addition, CCL2
has been implicated in the process that leads to
polarization of lymphocytes towards a Th1 or Th2
phenotype [6]. CCR2 (CC chemokine receptor 2)
represents the major receptor for CCL2, although some
actions of this chemokine are independent of CCR2
binding [7,8]. In the liver, increased CCL2 expression
has been shown in patients with acute and chronic
inflammatory diseases and in numerous rodent models
of injury [9,10]. Recently, the CCL2/CCR2 axis has
been suggested to be a mediator of adipose tissue
inflammation during obesity, favouring hepatic steatosis
[11,12]. Moreover, CCL2 expression is increased in the
liver of patients withNAFLD, where it is correlated with
fat accumulation [13,14]. However, the contribution of
this pathway to the development of steatohepatitis is
still uncertain. Recent studies by Kassel et al. [15] have
shown that CCL2 deficiency in C57Bl/6 mice did not
affect aminotransferase levels or inflammation in mice
fed on an MCD diet (methionine/choline-deficient diet)
for 4 weeks, whereas it down-modulated pro-fibrogenic
gene expression. As these results were in contrast with
findings in humans [14] and in other experimental models
of liver injury [9,10], and fibrosis is generally modest in
mice after 4 weeks on the MCD diet, we have studied
CCL2-KO (knockout) mice fed on the MCD diet for
8 weeks, a time point when fibrosis is well detectable. In
addition,we have conducted the experiments inmicewith
two different genetic backgounds. Our results indicate
that a lack of CCL2 reduces inflammation, oxidative
stress and fibrogenesis in Balb/C but not in C57Bl/6
mice, indicating that the effects of CCL2 deficiency are
markedly dependent on the mouse genetic background.
MATERIALS AND METHODS
Reagents
Unless otherwise indicated all chemicals were purchased
from Sigma.
Animals and experimental protocol
CCL2-KO mice (initial colony kindly provided by
Dr Barrett Rollins, Department of Medical Oncology,
Harvard University, Boston, MA, U.S.A.), backcrossed
with WT (wild-type) Balb/C mice for greater than ten
generations, have been described previously [16]. CCL2-
KO on a C57Bl/6J genetic background (referred to as
C57Bl/6) were obtained from Jackson Laboratories, and
a colony established. WT Balb/C or C57Bl/6 mice were
obtained from Harlan Nossan. In all experiments, 8-
week-old male mice were used, and six to eight animals
were included for each experimental point. All mice were
fed on a lipid-enriched MCD diet or the same diet
supplemented with the two amino acids (control diet)
for 8 weeks, as described previously [17].
Body weight was recorded weekly. At the end of the
study protocol, mice were anaesthetized and killed by
exsanguination, blood being collected from the inferior
vena cava. Blood was centrifuged and serum stored
for further analysis. Livers were rapidly dissected out,
weighed, snap-frozen in liquid nitrogen and kept at
− 80 ◦C for RNA and protein extraction. A portion
of the liver was immediately fixed in formalin for
histological analyses, and another portion was processed
for determination of oxidative-stress-related products
(see below).
All animals were treated with humane care, and
experimental protocols were performed according to
established international guidelines (Guide for the Care
and Use of Laboratory Animals, NIH publication no.
86-23) after approval by the local regulatory authorities.
Aminotransferase activity and
measurement of oxidative-stress-related
products
These determinations were carried out exactly as
described previously [16,17]. In particular, determination
of hepatic levels of ROS (reactive oxygen species) and
HNE (4-hydroxynonenal) were carried out on cytosolic
fractions obtained from the fresh liver tissue immediately
after the animals were killed.
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Table 1 FAM-labelled probes and primers (Applied
Biosystems) for specific genes or for the housekeeping
gene, GAPDH, used in the RT-PCR assays
Gene Primer ID
CD11b (Itgam) Mm00434455-m1
TNF Mm00443258-m1
TGF-β1 Mm00441724-m1
TIMP-1 Mm00441818-m1
Type-I procollagen Mm00801666-g1
α-Smooth muscle actin Mm01546133_m1
MGL1 Mm00546124_m1
IFN-γ Mm00801778_m1
IL-4 Mm00445259_m1
iNOS Mm00440485_m1
CCL5 Mm01302427_m1
GAPDH Mm99999915-g1
Liver histology
Fixation and staining of liver tissue were conducted as
described previously [17]. Liver histology was evaluated
by an experienced hepatopathologist blinded to the
type of treatment received by the animals. Scoring of
slides was performed using a semi-quantitative method,
as reported previously [17]. Quantification of fibrosis
was carried out by histomorphometric analysis using a
digital camera (DFC 320; Leica) coupled to a bright-field
microscope (DM4000; Leica), essentially as described
elsewhere [17].
Immunohistochemistry for MoMa2
Intrahepatic levels of MoMa2, a specific marker for
monocyte/macrophages, were determined by indirect
immunofluorescence performedon liver cryostat sections
(4 μm thick) as described previously [18]. Primary rat
monoclonal antibodies (1:50 dilution) were fromAbcam.
Immune positivity was revealed by the appropriate
secondary Cy3 (indocarbocyanine)-conjugated anti-
body (1:1000 dilution; Amersham Pharmacia Biotech).
Nuclei were stained using DAPI (4′,6-diamidino-2-
phenylindole) and slideswere examinedwith anOlympus
Fluoview 300 confocal laser scanning microscope.
Quantitative RT (real-time)-PCR
These experiments were carried out as described
previously [16,17]. The FAM (6-carboxyfluorescein)-
labelled probes and primers for the specific genes
or the housekeeping gene GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) are shown in Table 1.
All reagents were purchased from Applied Biosystems
(Foster City). Relative gene expression was calculated as
2−Ct (Ct = Ct of the target−Ct of GAPDH).
Table 2 Body weight and liver/body weight in WT and
CCL2-KO Balb/C mice subjected to different dietary
regimens
∗P < 0.05 compared with WT animals fed on the control diet.
Diet Body weight (g) Liver/body weight (×100)
Control diet
WT 22.56+− 2.00 4.33+− 0.24
CCL2-KO 21.88+− 1.21 4.61+− 0.41
MCD
WT 14.48+− 7.69∗ 4.79+− 0.47
CCL2-KO 12.59+− 1.22∗ 5.31+− 0.94
Isolation and culture of mouse hepatic
stellate cells
Hepatic stellate cells were isolated from three Balb/C
and three C57Bl/6 mice in parallel. Procedures for
isolation have been described in detail elsewhere [19].
After isolation, cells were cultured in a complete medium
until confluent, deprived of serum for 16 h, and utilized
for a chemotactic assay in response toCCL2, as described
previously [8].
Statistical analysis
Results are expressed as means +− S.D. Comparisons of
animal groups were analysed by Student’s t test or by
non-parametric tests, as appropriate. P values0.05 were
considered significant.
RESULTS
Lack of CCL2 protects Balb/C mice from
injury and inflammation
We first analysed the effects of an MCD diet given for
8 weeks toWTandCCL2-KOBalb/Cmice.At the endof
the treatment period, mice fed on theMCDdiet showed a
marked and significant decrease in body weight (Table 2).
However, no differences were observed comparing WT
and CCL2-KO mice with either diet regimen. The
liver/body weight ratio tended to be higher in mice fed
on the MCD diet (Table 2), but no significant differences
were found comparing the different diets or the different
mouse genotypes. In WT mice fed on the MCD diet,
the levels of ALT and AST (aspartate aminotransferase)
were increased more than 5-fold in comparison with
mice treated with the control diet (Figure 1). In contrast,
in mice lacking CCL2, aminotransferase levels were
significantly lower than in WT animals fed on the MCD
diet. No differences were observed comparing WT and
CCL2-KO mice fed on the control diet.
Feeding with an MCD diet is associated with
steatosis, hepatocellular injury and inflammation, which
recapitulate the histological picture observed in patients
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Figure 1 Lack of CCL2 reduces aminotransferase levels in
Balb/C mice
WT or CCL2-KO mice were fed for 8 weeks on the control diet or on the MCD
diet. WT Cnt, WT animals fed on the control diet; KO Cnt, CCL2-KO animals fed
on the control diet; WT MCD, WT animals fed on the MCD diet; KO MCD, CCL2-KO
animals fed on the MCD diet. At the end of the study protocol, animals were
killed and serum ALT (A) and AST (B) were assayed as described in Materials and
methods section. ∗P < 0.01 compared with WT animals fed on the control diet;
∗∗P < 0.01 compared with WT animals fed on the MCD diet. UI, international
units.
with NASH. In MCD-diet-fed WTmice, the appearance
of macrovescicular steatosis was accompanied by
infiltration with inflammatory cells and degenerative
changes in hepatocytes, including lobular necrosis
(Figures 2A–2D). In addition, aggregates of inflammatory
cells surrounding fat-laden hepatocytes were observed,
forming lipogranulomas. In CCL2-KO animals, no dif-
ferences in steatosis were evident, whereas inflammatory
changes were less marked, with a lower number of
inflammatory cell aggregates and less dense infiltrates
(Figures 2A–2D). When fed on a control diet, the
livers of CCL2-KO mice had a histological appearance
indistinguishable from that of WT mice. Blinded
evaluation of necro-inflammatory changes observed in
the different genotypes demonstrated an increased score
in WT mice fed on the MCD diet (Figure 2E). Necro-
inflammation was less severe in CCL2-KO mice fed on
an MCD diet, with an overall score significantly lower
than that of WT animals (Figure 2E). Scoring of steatosis
confirmed that no significant differences were present
comparing CCL2-KO andWTmice (results not shown).
CCL2 is one of the major chemoattactrants for
mononuclear cells, including monocytes. Thus we
immunostained the liver of different groups of mice
with MoMa2, which is an antibody recognizing an
intracellular antigen expressed by macrophages and
infiltrating monocytes (Figures 2F–2H). WT mice fed
on the MCD diet had an approximate 4-fold increase in
the percentage of MoMa2-positive cells compared with
those fed on the control diet (Figure 2F). A lack of CCL2
was associated with a significantly lower abundance
of monocytes/macrophages, which were approximately
half as many as in WT mice. In both genotypes of
mice fed on the control diet the MoMa2 antibodies
recognized Kupffer cells, and no differences were
observed (Figure 2F).
To provide further evidence for the protective effects of
CCL2 deficiency on inflammation, wemeasured the gene
expression of CD11b, a marker of inflammatory cells.
A 5-fold significant increase in CD11b expression was
observed inWTmice fed on theMCDdiet in comparison
with those fed on the control diet (Figure 3A). Expression
of CD11b was significantly reduced in MCD-diet-
fed CCL2-KO mice, confirming reduced inflammation
and in agreement with the results of the histological
examination. TNFα (tumour necrosis factor α) is a major
inflammatory cytokine and has been implicated in the
pathogenesis of NASH-associated hepatocyte damage
[3]. Transcripts encoding the TNFα gene were markedly
more abundant after feeding WT mice with the MCD
diet (Figure 3B), and also in this case CCL2 deficiency
reduced the expression of this cytokine.
CCL2 is involved in the generation of
oxidative stress in Balb/C mice
Increased generation of oxidative-stress-related products
is a hallmark of NASH and is reproduced by the MCD
model in rodents [20]. In Balb/C mice fed on the
MCD diet for 8 weeks, we analysed intrahepatic levels
of ROS and HNE, which represent the major oxidant
and non-oxidant products of oxidative stress respectively.
Both these compounds were significantly more abundant
in WT mice fed on the MCD diet than in those fed
on the control diet (Figures 3C and 3D). A lack of
CCL2 resulted significantly in lower levels of both ROS
and HNE in comparison with WT mice. These results
demonstrate that CCL2 contributes to the generation of
oxidative stress associated with the MCD diet in Balb/C
mice.
Fibrogenesis induced by the MCD diet is
modulated by the absence of CCL2 in
Balb/C mice
As in other forms of chronic liver damage, the MCD
diet triggers the initiation of a fibrogenic process that, in
mice, leads to accumulation of fibrillarmatrix after at least
8 weeks. To determine whether protection from necro-
inflammatory damage is associated with changes in fibro-
genesis, sections from mice fed on the control or MCD
diets were stained with Sirius Red (Figures 4A–4D).
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Figure 2 Effects of CCL2 deficiency on liver histology and inflammation following administration of an MCD diet in Balb/C
mice
WT or CCL2-KO mice were fed for 8 weeks on the control diet or the MCD diet. (A–D) At the end of the study protocol, animals were killed and liver sections were
stained with haematoxylin and eosin. (A) WT animals fed on the control diet (WT-Cnt); (B) CCL2-KO animals fed on the control diet (KO Cnt); (C) WT animals fed
on the MCD diet (WT MCD); (D) CCL2-KO animals fed on the MCD diet (KO MCD). (E) Individual necro-inflammatory scores in the four groups of mice are indicated.
(F) Cells positive for the monocyte/macrophage marker MoMa2 were counted in slides from each group of mice indicated as above. ∗P < 0.01 compared with WT
animals fed on the control diet; ∗∗P < 0.01 compared with WT animals fed on the MCD diet. (G,H) Representative immunofluorescence staining for MoMa2-positive
cells (green) in WT animals fed on the MCD diet (G) and CCL2-KO animals fed on the MCD diet (H).
As already described, administration of theMCDdiet for
8 weeks induced the matrix accumulation predominantly
in zone 3 of the hepatic acinus, with the appearance of
a ‘chickenwire’ pattern. Fibrosis was also detectable in
mice defective for CCL2, but in this case fibrotic bundles
appeared to be less thick and more sparse compared
with WT Balb/C mice. Computerized image analysis
of the slides stained with Sirius Red demonstrated that
in CCL2-KO mice accumulation of fibrillar collagen
was significantly reduced compared with WT animals
(Figure 4E).
To obtain further insight into the modulation of fibro-
genesis by CCL2 in this model, transcript levels of
genes implicated in hepatic wound healing and fibrosis
were evaluated. The epression of TGF-β (transforming
growth factor-β), a major pro-fibrogenic cytokine, was
significantly up-regulated by feeding the MCD diet in
WT Balb/C mice. This effect was significantly reduced
in CCL2-KO animals (Figure 4F). In a similar fashion,
up-regulated gene expression of type I procollagen,
and of TIMP-1 (tissue inhibitor of metalloproteinases-
1), were significantly reduced in mice lacking CCL2
(Figures 4G and 4H). In addition, the expression of
α-smooth muscle actin, which is a marker of hepatic
myofibroblasts, was markedly increased by the MCD
diet and significantly reduced in the absence of CCL2
(Figure 4I). No significant changes in the expression of
fibrogenic genes were observedwhen comparingWT and
CCL2-KO mice fed on the control diet. Taken together,
these results indicate that, in Balb/C mice, CCL2 is
involved in the fibrogenic progression of experimental
steatohepatitis induced by the MCD diet.
Injury, inflammation and fibrosis are not
affected by CCL2 deficiency in C57Bl/6
mice
Recently, Kassel et al. [15] investigated the development
of MCD-induced steatohepatitis in CCL2-KO mice
raised on a C57Bl/6 background, without detecting
significant differences in hepatic injury and inflammation
compared with WT mice. Since our findings obtained in
Balb/C mice demonstrate that CCL2 deficiency protects
from necro-inflammation and fibrosis, we also analysed
the effects of MCD feeding for 8 weeks and CCL2
deficiency in C57Bl/6 mice. In these mice, ALT levels
were elevated to a higher extent than in Balb/C mice
(approximately 7-fold). However, CCL2 deficiency did
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Figure 3 Lack of CCL2 reduces the expression of proinflammatory genes and limits generation of oxidative stress induced
by an MCD diet in Balb/C mice
WT or CCL2-KO mice were fed for 8 weeks on the control diet or the MCD diet. Groups are as in the legend to Figure 1. (A,B) At the end of the study protocol,
RNA was isolated from liver tissue and expression of CD11b (A) or of TNFα (B) was measured by RT-PCR. (C,D) A sample of fresh liver tissue was harvested, and
levels of ROS (C) and of HNE (D) were assayed as described in the Materials and methods sections. ∗P < 0.01 compared with WT animals fed on the control diet;
∗∗P < 0.01 compared with WT animals fed on the MCD diet. UF, units of fluorescence.
not result in any significant changes in ALT levels
(Figure 5A). In agreement with this observation, steatosis
(results not shown) and necro-inflammation (Figure 5B)
evaluated by histological scoring were not significantly
different when comparing the two genotypes. Moreover,
intrahepatic expression of the inflammatory marker
CD11b was increased to a similar extent in mice fed
on the MCD diet irrespective of the absence of CCL2
(Figure 5C).
We next evaluated whether a similar inflammatory
response to the MCD diet was associated with a similar
fibrogenic response in the absence of CCL2 in C57Bl/6
mice. Image analysis of the area stained with Sirius
Red demonstrated a marked and significant increase
in mice fed on the MCD diet compared with control
animals (Figure 6A). However, no differences comparing
WT mice and mice lacking CCL2 were observed. In
agreement with this observation, intrahepatic expression
of genes involved in fibrogenesis was not reduced in
the absence of CCL2 in C57Bl/6 mice fed on the
MCD diet, and the expression levels of α1-procollagen
were even higher (Figures 6C–6E). Accordingly,
α-smooth muscle actin expression, a marker of activated
myofibroblasts, was similar irrespective of the presence
of CCL2 (Figure 6E). These results demonstrate that
the effects of CCL2 on hepatic necro-inflammation and
fibrosis induced by the MCD diet are dependent on the
mouse genetic background.
Comparison of cytokine expression and of
macrophage polarization markers in mice
with different genetic backgrounds
To investigate the mechanisms underlying the different
inflammatory and fibrogenic response observed in the
two strains of mice upon CCL2 deletion, we first invest-
igated a group of cytokines involved in immune response
and inflammation. The levels of IFN-γ (interferon-γ ),
which promotes inflammation and is associated with a
lower fibrogenic response, were reduced by the MCD
diet in both Balb/C and C57Bl/6 mice, and no effects of
CCL2 deletion were observed (Figures 7A and 7B). In
contrast, the expression of IL (interleukin)-4, a cytokine
related to Th2 polarization, was reduced in Balb/C mice
fed on theMCDdiet, and the reductionwasmore evident
in the absence of CCL2 (Figure 7C). In contrast, in
C57Bl/6 mice, the levels of IL-4 were higher in animals
lacking CCL2 when fed on the MCD diet (Figure 7D).
To explore whether another member of the chemokine
family could compensate for the function of CCL2,
we analysed the expression of CCL5, a chemokine that
targets inflammatory cells and activated stellate cells [21].
Expression of CCL5 was only modestly changed by the
MCD diet in WT mice on both genetic backgrounds
(Figures 7E and 7F). In the absence of CCL2, a significant
increase inCCL5 expressionwas found to a similar extent
in both Balb/C and C57Bl/6 mice.
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Figure 4 Effects of CCL2 deficiency on the development of fibrosis induced by an MCD diet and expression of pro-fibrogenic
genes in Balb/C mice
WT or CCL2-KO mice were fed for 8 weeks on the control diet or the MCD diet. Groups are as in the legend to Figure 1. (A–D) At the end of the study protocol,
animals were killed and liver sections stained with Sirius Red. (A) WT animals fed on the control diet (WT-Cnt); (B) CCL2-KO animals fed on the control diet (KO Cnt);
(C) WT animals fed on the MCD diet (WT MCD); (D) CCL2-KO animals fed on the MCD diet (KO MCD). (E) Sirius-Red-stained slides were subjected to image analysis,
and the area occupied by fibrotic tissue was measured in WT and CCL2-KO mice fed on the control diet or the MCD diet. (F–I) RNA was isolated from liver tissue and
the expression of TGF-β (F), type I procollagen (G), TIMP-1 (H) and α-smooth muscle actin (I) were measured by RT-PCR. ∗P < 0.01 compared with WT animals
fed on the control diet; ∗∗P < 0.01 compared with WT animals fed on the MCD diet.
We finally analysed the expression of iNOS (inducible
NO synthase) and ofMGL1 (macrophage galactose-type
C-type lectin 1), markers of classically-activated (M1)
or alternatively-activated (M2)macrophages respectively.
In Balb/C mice, expression of iNOS was markedly
increased in response to the MCD diet, and lack of
CCL2 reduced the expression levels (Figure 7G), in
agreement with the milder inflammatory phenotype
of these mice (see Figures 2 and 3). iNOS was
only modestly increased in C57Bl/6 mice, and no
effects of CCL2 deficiency were observed. A different
behaviour comparing the two genetic backgrounds was
observed when MGL1 levels were measured. In fact,
this M2 polarization marker was expressed at lower
levels in MCD-diet-treated Balb/C mice lacking CCL2
(Figure 7I), and an opposite behaviour was found in
C57Bl/6 mice, where MGL1 levels increased in the
CCL2-deficient animals receiving the steatogenic diet
(Figure 7J). We also explored whether the chemotactic
effects of CCL2 on hepatic stellate cells could be different
in the two mouse strains. However, hepatic stellate
cells isolated from Balb/C or C57Bl/6 mice showed
a similar chemotactic response to CCL2 (results not
shown). Taken together, these results indicate that the
different effects of CCL2 deficiency on inflammation and
fibrogenesis caused by the MCD diet are associated with
differential expression of immune response cytokines and
macrophage polarization markers.
DISCUSSION
Hepatocellular damage, inflammation and fibrogenic
progression are the pivotal characteristics of steatohep-
atitis. Inflammatory chemokines, such as CCL2, are
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Figure 5 CCL2 deficiency does not affect aminotransferase levels and inflammation following administration of an MCD
diet in C57Bl/6 mice
WT or CCL2-KO mice were fed for 8 weeks on the control diet or the MCD diet. Groups are as in the legend to Figure 1. (A) Serum ALT was assayed as described in
Materials and methods section. (B) Individual necro-inflammatory scores in the four groups of mice. (C) RNA was isolated from liver tissue, and expression of CD11b
was measured by RT-PCR. U, units.
expressed at low levels in normal conditions, whereas
they are up-regulated following inflammatory damage
such as in NASH [13,22,23]. In the present study,
we provide evidence that in mice with experimental
steatohepatitis, the effects of deletion of CCL2 on hepatic
necro-inflammation and fibrogenesis are dependent on
the genetic background of the mice. In Balb/C mice,
modulation of hepatocellular injury and inflammation by
CCL2 is supported by several lines of evidence, including
a significant reduction of aminotransferase levels and
of histological necro-inflammatory score. In addition,
lack of CCL2 was associated with reduced expression
of several genes implicated in fibrogenesis, and the net
deposition of fibrillar matrix was significantly limited.
Moreover, accumulation of activated hepatic stellate cells,
as assessed by α-smooth muscle actin expression, was
decreased. Taken together, these data indicate that in
this genetic background, CCL2 plays a relevant role
in the pathogenesis of the changes that characterize
experimental steatohepatitis, including fibrosis.
Another important and novel finding of the
experiments conducted inBalb/Cmice, is the interference
of CCL2 with oxidative stress. Generation of oxidative
stress-related molecules has been suggested to be one of
the ‘multiple hits’ that are responsible for progression
of fatty liver to NASH [2,24]. Using state-of-the-
art techniques, we show that intra-hepatic generation
of ROS and reactive aldehydes such as HNE is
significantly lower when CCL2 is deleted in Balb/C
mice. These data become even more relevant in light
of the recent report demonstrating that antioxidants
may provide a clinical benefit to patients with NASH
[25].
Very recently, Kassel et al. [15] have reported the
effects of CCL2 deficiency in C57Bl/6 mice challenged
with an MCD diet for 4 weeks. No differences in
inflammation and liver injury were observed, whereas
a lower expression of genes involved in fibrogenesis was
reported. However, in the MCD diet model, fibrogenesis
is barely evident at 4 weeks, and time points longer
than 8 weeks are necessary to appropriately establish the
fibrogenic phenotype. For this reason, we investigated
in detail the inflammatory and fibrogenic phenotype
induced by the lack of CCL2 in C57Bl/6 mice on an
MCD diet for 8 weeks, when most of the animals have
unequivocal evidence of fibrosis. We confirmed that, in
this strain of mice, no differences in hepatic injury and
inflammation were associated with CCL2 deficiency, as
indicated by histological scoring and CD11b expression.
Surprisingly, we found that even fibrosis was not affected
by CCL2 deficiency, as shown by image analysis of
Sirius Red staining, expression of pro-fibrogenic genes,
and of genes indicating accumulation of activated stellate
cells.
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Figure 6 CCL2 deficiency does not affect the development of fibrosis or the expression of pro-fibrogenic genes following
administration of an MCD diet in C57Bl/6 mice
WT or CCL2-KO mice were fed for 8 weeks on the control diet or the MCD diet. Groups are as in the legend to Figure 1. (A) Sirius-Red-stained slides were subjected
to image analysis, and the area occupied by fibrotic tissue was measured in WT and CCL2-KO mice fed on a control diet or an MCD diet. (B–E) RNA was isolated
from liver tissue and the expression of TGF-β (B), type I procollagen (C), TIMP-1 (D) and α-smooth muscle actin (E) were measured by RT-PCR. ∗P < 0.01 compared
with WT animals fed on the control diet; ∗∗P < 0.01 compared with WT animals fed on the MCD diet.
Interestingly, both our study and the one of Kassel
et al. [15] demonstrate the lack of effect of CCL2
deficiency on steatosis, irrespective of the inhibition of
inflammation. These findings are probably dependent
on the mechanisms that lead to steatosis in the
MCD diet model, where impaired VLDL release is
a major determinant of triacylglycerol (triglyceride)
accumulation. This pathogenic mechanism is probably to
be poorly sensitive to changes in inflammation possibly
associated with CCL2 deficiency.
The different inflammatory and fibrogenic phenotype
associatedwithCCL2deficiency in the twomouse strains
is a very intriguing finding. For this reason, we
conducted additional experiments to elucidate possible
mechanisms of the diverging phenotypes observed in
the absence of CCL2. We first tested the possibility
that hepatic stellate cells isolated from the two mouse
strains could be differentially responsive to CCL2
in vitro. However, a similar chemotactic index was
found incubating with CCL2 stellate cells from Balb/C
or C57Bl/6 mice, ruling out the possibility of a lack
of response to CCL2 as a mechanism for defective
protection from fibrosis in C57Bl/6 mice. Next, we
measured the expression of different cytokines implicated
in inflammation and immune response and of markers
of cytokine polarization. Analysis of the expression of
cytokines implicated in the polarization toward a Th1 or
Th2 phenotype, revealed a partially divergent response in
the two strains of mice. Specifically, while the expression
of IFN-γ was substantially similar, expression of IL -4, a
Th2 cytokine, was significantly increased in MCD diet-
treated, CCL2-deficient mice on a C57Bl/6 background,
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Figure 7 Differential expression of genes involved in inflammation and immune response in mice with a different genetic
background fed on the MCD diet
WT or CCL2-KO mice on a Balb/C (A, C, E, G, I) or C57Bl/6 (B, D, F, H, J) genetic background were fed for 8 weeks on the control diet or on the MCD diet. At
the end of the study protocol, RNA was isolated from liver tissue and the expression of IFN-γ (A,B), IL-4 (C,D), CCL5 (E,F), iNOS (G,H) or MGL1 (I,J) was assayed by
RT-PCR. ∗P < 0.01 compared with WT animals fed on the control diet; ∗∗P < 0.01 compared with WT animals fed on the MCD diet.
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but not in the corresponding group on the Balb/C
background. It is well established that a Th2-polarized
response is associated with more marked fibrogenesis
during injury in many tissues, including the liver [26–28].
In addition, IL-4 has been found to directly modulate the
fibrogenic properties of hepatic myofibroblasts, resulting
in increased expression of extracellular matrix [29,30].
Thus, it is likely that increased IL-4 expression and
possibly a general skewing towards a Th2 response
contribute to the maintenance of fibrogenesis despite the
lack of CCL2.
Another interesting finding revealed by cytokine
expression analysis in the two genetic backgrounds is
the increased expression of MGL1, a marker related
to alternative macrophage activation, in C57Bl/6 mice
on an MCD diet. In recent years, classically activated
(M1) macrophages, mostly involved in tissue injury
and inflammation, and M2, or alternatively activated
macrophages, implicated in the process of tissue repair,
have been described and characterized [31]. It should
be kept in mind that M1 or M2 macrophages represent
extremes of a continuum in a universe of activation
states that are still incompletely characterized [32].
Nonetheless, the finding that a lack of CCL2 in C57Bl/6
mice fed on the MCD diet might show a greater M2
polarization suggests a possible additional mechanism
responsible for the maintenance of a fibrogenic stimulus.
In fact, M2 polarization is generally associated with
Th2 lymphocyte polarization and with expression of
pro-fibrogenic factors, such as TGF-β [31]. In addition,
several conditions characterized by chronic tissue injury
and a fibrogenic evolution are associatedwith an infiltrate
that comprises M2 macrophages.
Besides the conserved fibrogenesis, CCL2-deficient,
MCD diet-treated C57Bl/6 mice also have comparable
inflammation with respect to the Balb/C counterpart. We
hypothesized that, in C57Bl/6 mice, CCL2 deficiency
in mice fed on the MCD diet could be compensated
by an increase in other chemokines involved in the
recruitment of inflammatory cells. Thus we tested
the expression of CCL5, a chemokine that targets both
inflammatory and fibrogenic cells, and found a marked
increase in comparison with WT mice on the same
genetic background. However, a similar behaviour was
observed in Balb/C mice, indicating that CCL5 is not
responsible for the lack of protection from inflammation
observed in C57Bl/6. Interestingly, in some systems,
including the adipose tissue, infiltration with M2-
polarizedmacrophages has been associatedwith amarked
infiltration of M1-polarized cells [33]. These results
indicate that the general concept that M2 macrophages
are anti-inflammatorymay not be applied to all situations
and allows us to speculate that increasedM2macrophages
in C57Bl/6 mice could contribute to the maintenance
of inflammation. Clearly, additional studies, including
a wide-spectrum analysis of cytokine expression and
inflammatory cell phenotypes are required to provide
detailed information on the mechanisms underlying
the differences between the two genetic backgrounds.
Although the mechanisms underlying the different
inflammatory response observed comparingC57Bl/6 and
Balb/C mice fed on the MCD diet remain incompletely
resolved, these results suggest that genetic differences
may be responsible for a different inflammatory response
in patients with steatohepatitis. Along these lines, the
severity of NASH progression has been shown to
change according to the different genetic backgrounds of
the patients [34], and the possibility that variations in the
inflammatory response contributes to these observations
warrants further studies.
In principle, CCL2 appears to be an appealing target
in human steatohepatitis. Besides its well-established role
on inflammation, CCL2 has been shown to directly
modulate the biology of fibrogenic cells, suggesting the
possibility that interference with this chemokine directly
blocks fibrosis [8,35]. This is supported by elegant studies
in chimaeric mice, where deletion of CCR2, the receptor
for CCL2, in liver resident cells, including hepatic stellate
cells, was sufficient to inhibit the fibrogenic response [36].
Moreover, CCL2 has been shown to play a detrimental
role in adipose tissue inflammation [11,12], favouring the
release of non-esterified ‘free’ fatty acids and leading to
adipokine imbalance. Very recently, a pharmacological
inhibitor of CCL2 was found to block inflammation and
steatosis, but not fibrosis, in the MCD diet model of
steatohepatitis in C57Bl/6 mice [37]. The reasons for
the discrepancy with the results of our present study
and that of Kassel et al. [15] are unclear, but may
be based on the fact that we utilized CCL2-KO mice
in which compensatory mechanisms may have taken
place. Results provided herein, highlighting the different
response of mice with different genetic backgrounds,
make the translation of these proof-of-concept studies
more difficult. It can be speculated that interfering with
CCL2 may prove to be beneficial only in a group
of patients, although genetic differences in rodents do
not necessarily parallel the genetic diversity of humans.
Although additional work in experimental models is
warranted to shed further light on the role of this
chemokine in mouse steatohepatitis, there is still a strong
rationale to investigate approaches that lead to diminished
effects of CCL2 in patients withNASH, considering that
chemokines and their receptors are also the focus of
considerable attention as drug targets [38].
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